|
- Evidence-based treatments for eosinophilic esophagitis: insights for . . .
Formulations of STC originally designed for asthma therapy are suboptimal for EoE treatment, with new effervescent orodispersible tablets and viscose formulations designed to coat the esophageal mucosa providing increased effectiveness at reduced doses Pharmacological treatments for eosinophilic esophagitis: current options and emerging
- How New Drug Approvals are Reshaping Treatment for Eosinophilic Esophagitis
The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes
- First FDA-Approved Treatment for Eosinophilic Esophagitis Has Roots in . . .
The first Food and Drug Administration approval of a treatment for eosinophilic esophagitis, This scientific foundation, among many other factors, led Regeneron Pharmaceuticals Inc of Tarrytown, New York, and Sanofi of Paris to begin testing one of their drugs for the treatment of EoE The drug, a monoclonal antibody called dupilumab
- Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
A gene expression panel is accurate for diagnosis and monitoring treatment of eosinophilic esophagitis in adults Clin Transl Gastroenterol 2017;8(2 A F , G D Y , J M ) — both in New York
- FDA Approves EOHILIA (budesonide oral suspension) - Takeda
EOHILIA is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE) EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks Important Safety Information Contraindications
- Eosinophilic esophagitis: promising therapy, biomarkers, and assessment . . .
New diagnostic, monitoring, and treatment approaches are available for eosinophilic gastrointestinal diseases, including breakthroughs in eosinophilic esophagitis with new biologics and biomarkers The recent approval of dupilumab for treatment of eosinophilic esophagitis (EOE), research into better biomarkers, and the anticipated availability
- The New Therapeutic Frontiers in the Treatment of Eosinophilic . . . - PubMed
Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs Int J Mol Sci 2024 Jan 30;25(3):1702 doi: 10 3390
- FDA Grants Orphan Drug Designation to ‘1104, First-In-Class Peptide for . . .
The FDA has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class immune-resetting peptide (Revolo Biotherapeutics) designed to treat eosinophilic esophagitis (EoE) The ODD offers support in developing potential new medicines, treatment, and diagnostic tools to prevent rare conditions that impact fewer than 200,000 individuals in
|
|
|